Shortly after arriving in Ottawa with her two young children, following her husband's appointment as Cameroon's High Commissioner (Ambassador) to Canada, Mercy Azoh-Mbi complained of fatigue, fever, a ...

Mars is a strange place and any humans born there are bound to look radically different over thousands or even hundreds of ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

With that in mind, let's consider two stocks that haven't performed well recently and are now near their 52-week lows but ...

CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

SAN FRANCISCO — Eleven years ago, Editas launched as the first company built around the nascent gene editing technology CRISPR. Founded by Feng Zhang, George Church, and others and backed by ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

CRISPR is a powerful gene-editing tool that holds enormous potential for treating genetic diseases by allowing scientists to ...

An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...